JP5844045B2 - 疾病の薬理シャペロン治療に対する応答性を予測する方法 - Google Patents

疾病の薬理シャペロン治療に対する応答性を予測する方法 Download PDF

Info

Publication number
JP5844045B2
JP5844045B2 JP2010546901A JP2010546901A JP5844045B2 JP 5844045 B2 JP5844045 B2 JP 5844045B2 JP 2010546901 A JP2010546901 A JP 2010546901A JP 2010546901 A JP2010546901 A JP 2010546901A JP 5844045 B2 JP5844045 B2 JP 5844045B2
Authority
JP
Japan
Prior art keywords
activity
gala
host cell
pharmacological chaperone
gal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010546901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011514152A (ja
Inventor
エルフリダ・ベンジャミン
ブイ・ハング・ド
ウ・シャオヤン
ジョン・フラナガン
ブランドン・ウストマン
Original Assignee
アミカス セラピューティックス インコーポレイテッド
アミカス セラピューティックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40957500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5844045(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アミカス セラピューティックス インコーポレイテッド, アミカス セラピューティックス インコーポレイテッド filed Critical アミカス セラピューティックス インコーポレイテッド
Publication of JP2011514152A publication Critical patent/JP2011514152A/ja
Application granted granted Critical
Publication of JP5844045B2 publication Critical patent/JP5844045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
JP2010546901A 2008-02-12 2009-02-12 疾病の薬理シャペロン治療に対する応答性を予測する方法 Active JP5844045B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US2814108P 2008-02-12 2008-02-12
US61/028,141 2008-02-12
US3568408P 2008-03-11 2008-03-11
US61/035,684 2008-03-11
US9363108P 2008-09-02 2008-09-02
US61/093,631 2008-09-02
US11349608P 2008-11-11 2008-11-11
US61/113,496 2008-11-11
PCT/US2009/033963 WO2009102895A2 (en) 2008-02-12 2009-02-12 Method to predict response to pharmacological chaperone treatment of diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014244283A Division JP2015091239A (ja) 2008-02-12 2014-12-02 疾病の薬理シャペロン治療に対する応答性を予測する方法

Publications (2)

Publication Number Publication Date
JP2011514152A JP2011514152A (ja) 2011-05-06
JP5844045B2 true JP5844045B2 (ja) 2016-01-13

Family

ID=40957500

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2010546901A Active JP5844045B2 (ja) 2008-02-12 2009-02-12 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2014244283A Pending JP2015091239A (ja) 2008-02-12 2014-12-02 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2016039171A Active JP6672013B2 (ja) 2008-02-12 2016-03-01 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2018245609A Active JP6837469B2 (ja) 2008-02-12 2018-12-27 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2021019383A Active JP7277493B2 (ja) 2008-02-12 2021-02-09 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2023076515A Withdrawn JP2023109807A (ja) 2008-02-12 2023-05-08 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2025097940A Pending JP2025148351A (ja) 2008-02-12 2025-06-11 疾病の薬理シャペロン治療に対する応答性を予測する方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2014244283A Pending JP2015091239A (ja) 2008-02-12 2014-12-02 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2016039171A Active JP6672013B2 (ja) 2008-02-12 2016-03-01 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2018245609A Active JP6837469B2 (ja) 2008-02-12 2018-12-27 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2021019383A Active JP7277493B2 (ja) 2008-02-12 2021-02-09 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2023076515A Withdrawn JP2023109807A (ja) 2008-02-12 2023-05-08 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2025097940A Pending JP2025148351A (ja) 2008-02-12 2025-06-11 疾病の薬理シャペロン治療に対する応答性を予測する方法

Country Status (16)

Country Link
US (8) US8592362B2 (enExample)
EP (4) EP2252313B1 (enExample)
JP (7) JP5844045B2 (enExample)
AU (7) AU2009214648B2 (enExample)
CA (1) CA2715407C (enExample)
CY (3) CY1116466T1 (enExample)
DK (3) DK3470077T3 (enExample)
ES (3) ES2541933T3 (enExample)
HR (3) HRP20150728T1 (enExample)
HU (3) HUE026543T2 (enExample)
LT (2) LT3470077T (enExample)
MX (1) MX2010008835A (enExample)
PL (3) PL3470077T3 (enExample)
PT (3) PT2946785T (enExample)
SI (3) SI3470077T1 (enExample)
WO (1) WO2009102895A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2652553C (en) 2006-05-16 2020-08-18 Amicus Therapeutics, Inc. Use of 1-deoxygalactonojirimycin or a salt thereof in the treatment of fabry disease
LT3470077T (lt) 2008-02-12 2021-02-25 Amicus Therapeutics, Inc. Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas
AU2009223125A1 (en) * 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for Pompe disease
AR078498A1 (es) * 2009-10-01 2011-11-09 Baylor Res Inst Tratamiento de calvicie de patron masculino por induccion local del defecto metabolico de la enfermedad de fabry
US20120283290A1 (en) * 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
SG10202003753PA (en) 2014-09-30 2020-05-28 Amicus Therapeutics Inc Highly potent acid alpha-glucosidase with enhanced carbohydrates
AU2016233135B2 (en) 2015-03-19 2021-07-08 Translate Bio, Inc. mRNA therapy for pompe disease
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CA3010205A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
SMT202100452T1 (it) 2015-12-30 2021-09-14 Amicus Therapeutics Inc Alfa-glucosidasi acida potenziata per il trattamento della malattia di pompe
KR20190087673A (ko) 2016-03-22 2019-07-24 아미쿠스 세라퓨틱스, 인코포레이티드 Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법
CN109475607B (zh) 2016-03-30 2022-04-26 阿米库斯治疗学公司 包含重组酸性α-葡糖苷酶的配制品
KR20250017756A (ko) 2016-03-30 2025-02-04 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
SG11201808592PA (en) * 2016-03-30 2018-10-30 Amicus Therapeutics Inc Method for selection of high m6p recombinant proteins
EP4378524A3 (en) 2016-07-19 2024-08-14 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naive and ert-experienced patients
JP6546135B2 (ja) 2016-08-24 2019-07-17 株式会社ノリタケカンパニーリミテド 積層造形焼成体、積層造形焼成体の製造方法および積層造形焼成体製造用キット
ES3047063T3 (en) * 2016-10-20 2025-12-03 Sangamo Therapeutics Inc Methods and compositions for the treatment of fabry disease
EA039750B1 (ru) * 2017-03-30 2022-03-10 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
EP4223310A3 (en) 2017-05-15 2023-10-11 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
TW202322814A (zh) 2017-05-30 2023-06-16 美商阿米庫斯醫療股份有限公司 治療有腎損傷的法布里患者的方法
WO2018222655A1 (en) 2017-05-30 2018-12-06 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
WO2019017938A1 (en) 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES
JP7755929B2 (ja) 2017-08-28 2025-10-17 アミカス セラピューティックス インコーポレイテッド ファブリー病患者における心臓機能の強化及び／または安定化方法
CN112203657A (zh) 2018-02-06 2021-01-08 阿米库斯治疗学公司 患有经典法布里病的患者的治疗
WO2019157047A1 (en) 2018-02-06 2019-08-15 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
KR20210046729A (ko) 2018-08-20 2021-04-28 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
NL2021840B1 (en) 2018-10-19 2020-05-13 Univ Leiden Pharmacological Chaperones For Enzyme Treatment Therapy
WO2020046132A1 (en) 2018-08-31 2020-03-05 Leiden University Pharmacological chaperones for enzyme treatment therapy
TW202042812A (zh) 2019-01-22 2020-12-01 美商阿米庫斯醫療股份有限公司 減少法布瑞氏症患者中之腦血管事件之方法
CA3141226A1 (en) 2019-06-11 2020-12-17 Franklin Johnson Methods of treating fabry disease in patients having renal impairment
US11833164B2 (en) * 2019-08-07 2023-12-05 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
US20230220320A1 (en) 2019-09-06 2023-07-13 Amicus Therapeutics, Inc. Method For Capturing And Purification Of Biologics
SI4114390T1 (sl) * 2020-03-06 2025-03-31 Amicus Therapeutics, Inc. Postopki zdravljenja Fabryjeve bolezni pri bolnikih z mutacijo gena GLA
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
US20240293387A1 (en) 2021-07-12 2024-09-05 Amicus Therapeutics, Inc. Methods of Treating Fabry Disease in Pediatric Patients
KR20250007602A (ko) 2022-05-05 2025-01-14 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료에 대한 방법
KR20250110931A (ko) 2022-12-02 2025-07-21 아미쿠스 세라퓨틱스, 인코포레이티드 소아 환자의 영아-발병 폼페병 치료에 대한 방법
CN121057588A (zh) 2022-12-02 2025-12-02 阿米库斯治疗学公司 用于在儿科患者中治疗迟发性庞贝病的方法
US20240197706A1 (en) 2022-12-13 2024-06-20 Amicus Therapeutics, Inc. Methods of improving the pharmacokinetics of migalastat

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21381A (en) * 1858-08-31 Bracelet
US203019A (en) * 1878-04-30 Improvement in circuits for acoustic or telephonic telegraphs
US270486A (en) * 1883-01-09 Bundle-separating attachment for self-binding harvesters
US264467A (en) * 1882-09-19 Chables h
US3586908A (en) 1969-02-28 1971-06-22 Robert E Vosteen Automatic potential control system for electrophotography apparatus
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5863903A (en) 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
US5844102A (en) 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
JP2000509971A (ja) 1996-04-10 2000-08-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 化学的シャペローンを用いる遺伝的欠陥の修正
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US6244113B1 (en) 1999-10-29 2001-06-12 University Of Alabama In Huntsville Method and apparatus for measuring microgravity acceleration
US7842470B2 (en) * 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
JP2008545657A (ja) * 2005-05-17 2008-12-18 アミカス セラピューティックス インコーポレイテッド １−デオキシノジリマイシンおよび誘導体を用いるポンペ病の治療方法
KR20080033242A (ko) * 2005-06-08 2008-04-16 아미쿠스 세라퓨틱스, 인코포레이티드 리소좀 효소를 코딩하는 유전자의 돌연변이와 관련있는ｃｎｓ 질환의 치료 방법
WO2008045015A1 (en) 2005-06-08 2008-04-17 Amicus Therapeutics, Inc. Imino and amino sugar purification
US7790364B2 (en) * 2006-01-27 2010-09-07 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for high throughput screening of pharmacological chaperones
CA2652553C (en) 2006-05-16 2020-08-18 Amicus Therapeutics, Inc. Use of 1-deoxygalactonojirimycin or a salt thereof in the treatment of fabry disease
PL1860101T3 (pl) 2006-05-24 2011-10-31 Amicus Therapeutics Inc Sól winianu izofagominy i sposoby zastosowania
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
LT3470077T (lt) 2008-02-12 2021-02-25 Amicus Therapeutics, Inc. Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas
US8321148B2 (en) 2008-10-24 2012-11-27 Amicus Therapeutics, Inc. Multiple compartment dosing model
ES2585584T3 (es) 2009-05-26 2016-10-06 Amicus Therapeutics, Inc. Utilización de chaperonas farmacológicas para mejorar la fabricación y la purificación de ß-glucosidasa ácida
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
JP5739898B2 (ja) 2009-11-17 2015-06-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 心疾患マーカーとしての尿中トリアオシルセラミド（ｇｂ３）
CN103974619B (zh) 2011-03-11 2017-02-15 阿米库斯治疗学公司 治疗法布里病的给药方案
EP2874648A4 (en) 2012-07-17 2015-12-30 Amicus Therapeutics Inc CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
KR20190087673A (ko) 2016-03-22 2019-07-24 아미쿠스 세라퓨틱스, 인코포레이티드 Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법
EP4378524A3 (en) 2016-07-19 2024-08-14 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naive and ert-experienced patients
JP2020503900A (ja) 2017-01-10 2020-02-06 アミカス セラピューティックス インコーポレイテッド ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ
WO2018222655A1 (en) 2017-05-30 2018-12-06 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
WO2019017938A1 (en) 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES
JP7755929B2 (ja) 2017-08-28 2025-10-17 アミカス セラピューティックス インコーポレイテッド ファブリー病患者における心臓機能の強化及び／または安定化方法
CN112203657A (zh) 2018-02-06 2021-01-08 阿米库斯治疗学公司 患有经典法布里病的患者的治疗
WO2019157047A1 (en) 2018-02-06 2019-08-15 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
KR20210046729A (ko) 2018-08-20 2021-04-28 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
CA3141226A1 (en) 2019-06-11 2020-12-17 Franklin Johnson Methods of treating fabry disease in patients having renal impairment
US11833164B2 (en) 2019-08-07 2023-12-05 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene

Also Published As

Publication number Publication date
PT2946785T (pt) 2019-02-01
US9545397B2 (en) 2017-01-17
AU2019219727B2 (en) 2021-05-20
SI3470077T1 (sl) 2020-12-31
EP3824900A1 (en) 2021-05-26
AU2009214648A1 (en) 2009-08-20
HUE026543T2 (hu) 2016-06-28
MX2010008835A (es) 2010-10-20
US20250082621A9 (en) 2025-03-13
AU2014221321A1 (en) 2014-10-02
DK3470077T3 (da) 2020-11-30
CY1116466T1 (el) 2017-03-15
EP3470077A1 (en) 2019-04-17
HRP20201827T1 (hr) 2021-01-08
JP6672013B2 (ja) 2020-03-25
HUE051377T2 (hu) 2021-03-01
SI2946785T1 (sl) 2019-02-28
EP2946785B1 (en) 2018-10-24
US10813921B2 (en) 2020-10-27
LT2946785T (lt) 2019-02-11
USRE48608E1 (en) 2021-06-29
US20210251971A1 (en) 2021-08-19
JP6837469B2 (ja) 2021-03-03
JP2011514152A (ja) 2011-05-06
AU2014221321B2 (en) 2016-05-12
EP2946785A1 (en) 2015-11-25
ES2716502T3 (es) 2019-06-12
CY1123816T1 (el) 2022-03-24
AU2009214648B2 (en) 2014-11-13
US20110152319A1 (en) 2011-06-23
CA2715407A1 (en) 2009-08-20
AU2021218172A1 (en) 2021-10-07
JP7277493B2 (ja) 2023-05-19
LT3470077T (lt) 2021-02-25
AU2016206297A1 (en) 2016-08-04
AU2024219997A1 (en) 2024-10-10
HRP20190143T1 (hr) 2019-03-22
ES2836121T3 (es) 2021-06-24
SI2252313T1 (sl) 2015-08-31
EP2252313B1 (en) 2015-04-08
AU2017268649A1 (en) 2018-01-04
HRP20150728T1 (hr) 2015-08-14
PT2252313E (pt) 2015-08-26
US20140206721A1 (en) 2014-07-24
WO2009102895A3 (en) 2009-12-23
US20110212996A1 (en) 2011-09-01
PL3470077T3 (pl) 2021-04-06
JP2016163571A (ja) 2016-09-08
EP2252313A4 (en) 2011-04-13
US9095584B2 (en) 2015-08-04
WO2009102895A2 (en) 2009-08-20
US20170003301A1 (en) 2017-01-05
HUE042882T2 (hu) 2019-07-29
JP2023109807A (ja) 2023-08-08
JP2021097673A (ja) 2021-07-01
US8592362B2 (en) 2013-11-26
US20150342940A1 (en) 2015-12-03
JP2025148351A (ja) 2025-10-07
EP3470077B1 (en) 2020-08-26
PL2252313T3 (pl) 2015-09-30
CA2715407C (en) 2022-07-26
DK2252313T3 (en) 2015-07-13
US20190000818A1 (en) 2019-01-03
PL2946785T3 (pl) 2019-04-30
DK2946785T3 (en) 2019-02-18
JP2015091239A (ja) 2015-05-14
CY1121386T1 (el) 2020-05-29
ES2541933T3 (es) 2015-07-28
JP2019088289A (ja) 2019-06-13
EP2252313A2 (en) 2010-11-24
AU2019219727A1 (en) 2019-09-12
PT3470077T (pt) 2020-11-30

Similar Documents

Publication Publication Date Title
JP7277493B2 (ja) 疾病の薬理シャペロン治療に対する応答性を予測する方法
HK40053489A (en) Method to predict response to pharmacological chaperone treatment of diseases
HK40007672A (en) Method to predict response to pharmacological chaperone treatment of diseases
HK40007672B (en) Method to predict response to pharmacological chaperone treatment of diseases

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131219

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140220

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140417

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151020

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151118

R150 Certificate of patent or registration of utility model

Ref document number: 5844045

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250